Current and Emerging Microbiology Tests: Emerging Assays and Companies Developing New Technologies and Products
NEW YORK, Dec. 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0591317/Current-and-Emerging-Microbiology-Tests-Emerging-Assays-and-Companies-Developing-New-Technologies-and-Products.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic
This 650-page report provides a comprehensive marketing and technological assessment, as well as medical rationale and diagnostic prospects for nearly 80 infectious diseases and viruses, including their scientific background, clinical significance and market needs for both current and emerging tests, vaccines, drugs and extensive listings of companies developing or marketing new technologies and products.
Contains 650 pages and 47 tables
Table of Contents
1. AIDS
a. Background
Structure and Composition
Classification
Origin of AIDS
Animal Lentivirus Systems
Virus Receptos
HIV Infections in Humans
- Pathogenesis & Pathology: Overview of
HIV Infection Course
CD4T Lymphocytes and Memory Cells
Monocytes and Macrophages
Lymphoid Organs
Neural Cells
Viral Coinfections
- Clinical Findings
Plasma Viral Load
Pediatric AIDS
- Neurologic Disease
- Opportunistic Infections
- Cancer
Immunity
- Virus Isolation
- Serology
- Detection of Viral Nucleic
Acid and Antigens
Infectivity
Epidemiology
- Worldwide Spread of AIDS
- United States
- Routes of Transmission
b. Diagnostic Tests
Laboratory Diagnosis
- Enzyme Immunoassay Interpretation
- Specific, Sensitivity, and Predictive
Value of Enzyme Immunoassays
Competition Assays
Western Blot Technique
Immuno-Fluorescence Assay (IFA)
Radioimmunoprecipitation
HIV-1/HIV-2 Combination Testing
Methods of HIV-Antigen Detection
Antigen Assays and Blood Screening
Urine Tests
Immunopathogenic Mechanism of HIV Infection
DNA Probes
- Overview
- Quantitative Polymerase Chain Reaction
- In Situ PCR
- Needed Improvements
Viral Load/Drug Resistance Testing
Genotype and Phenotype Testing
Blood Banking Consideration
c. Vaccines and Drugs
- Antiviral Drugs
- Vaccines Against HIV
Transmission of HIV in Blood Products
HIV Transmission in Transplant and
Artificial Insemination Recipients
2. Adenovirus
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
d. Adeno-Associated Viruses(AAV)
3. Aeromonas
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
4. Anthrax/Bacillus Anthracis
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
5. Arboviruses
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
6. Babesiosis
a. Background
7. Bacillary Epithelioid Angiomatosis (BEA)
And Other Bartonella (Rochalimaea)
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
8. Blastocystis Hominis
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
9. Brucella
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
10. Campylobacter
a. Background
b. Diagnostic Tests
Identification from Culture
c. Vaccines and Drugs
11. Candida
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
12. Chagas Disease
a. Background
13. Chancroid
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
14. Chlamydia
a. Background
Chlamydia Psittaci
Chlamydia Pneumoniae
Chlamydia Trachomatis
b. Diagnostic Tests
c. Vaccines and Drugs
15. Clostridium Difficile
a. Background
Pediatric Infections
Epidemiology
b. Diagnostic Tests
Counter immuno electrophoresis
Fluorescent-Antibody Assays
Poloymerase Chain Reactions
c. Drugs and Vaccines
16. Coronaviruses
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
17. Coxsackieviruses
a. Background
Herpangina
Hand-foot-and-mouth syndrome
Hepidemic Conjuctivitis
Pharingitis
Epidemic Pleurodynia
Myodarditis, Pericarditis
Overwhelming Infection of the Newborn
Acute Aseptic Meningitis
Undifferentiated Febrile Illness
Fever with upper respiratory infection
Encephalitis
Asymptomatic Infection
b. Diagnostic Tests
c. Vaccines and Drugs
18. Creutzfeldt-Jakob's Disease
a. Background
Blood Transmission
b. Diagnostic Tests
Major Commercial and Academic Players
- Bayer
- Disease Sciences/Bio Tec Global
- Imperial College of Medicine
- Ortho-Clinical Diagnostics
- Pall
- ProMetic Life Sciences
- Proteome Sciences/Idexx
- Q-One Biotech
- Serono
- U.S. Agricultural Research Service
c. Vaccines
19. Cryptosporidium Parvum
a. Background
b. Diagnostic Tests
Histologic
Laboratory Parasitology
Serodiagnosis
c. Vaccines and Drugs
20. Cyclospora Cayetanensis
a. Background
Asymptomatic Infection
Diarrhea in Immunocompetent Persons
Diarrhea in Immunocompromisedersons
b. Diagnostic Tests
c. Vaccines and Drugs
21. Cytomegalovirus
a. Background
Chorioretinitis
Gastrointestinal
Central Nervous System Disease
b. Diagnostic Tests
c. Vaccines and Drugs
22. Ebola Virus
a. Background
Epidemiology
Hemorrhagic Fever
b. Diagnostic Tests
c. Vaccines and Drugs
23. E. Coli
a. Background
Role of Escherichia Coli in
Causing Diarrhea
EPEC
ETEC
EIEC
EHEC
b. Diagnostic Tests
c. Vaccines and Drugs
24. EchoVirus
a. Background
Acute Aseptic Miningitisis
Encephalitis
Exanthems
Respiratory Disease
Myope;ricarditis
Neonatal Infections
b. Diagnostic Tests
c. Vaccines and Drugs
25. Encephalitis
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
26. Enteroviruses
a. Background
b. Diagnostic Tests
Viral Isolation and Identification
Antibody Tests
c. Vaccines and Drugs
27. Epstein-Barr Virus
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
28. Giardia Lamblia
a. Background
Life Cycle and Morphology
Morphology of Trophozoites
Clinical Disease
b. Diagnostic Tests
c. Vaccines and Drugs
29. Gonorrhea
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
30. Granuloma Inguinale
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
31. Hantavirus
a. Background
Identification of the Agent
Transmission
Other Rodent Hantaviruses
Distribution
Hantavirus Diseases
Epidemiology
Addendum in Proof-Northeastern Connection
Previously Unknown Pathogens
Cases Nationwide
b. Diagnostic Tests
An Immunohistochemistry Approach
Hantavirus Rapid Diagnostic Test
ELISA Diagnosis of Hantavirus Pulmonary
Syndrome
IgG ELISA
IgM Capture ELISA
c. Vaccines and Drugs
32. Helicobacter Pylori
a. Background
Pathogenesis
Role in Peptic Ulcer Disease
Role in Gastric Cancer
Nonulcer Dyspepsia
b. Diagnostic Tests
c. Vaccines and Drugs
Specific Therapeutic Regimens
Who Should Be Treated?
Participants in Controlled Clinical Trials
Patients with Refractory Peptic Ulcer
Patients with Refractory NUD
Patients in High-Risk Groups for Gastric
Cancer
33. Hepatitis
a. Background
b. Hepatitis A
c. Hepatitis B
d. Hepatitis C
Classification
Transmission of Infection
Occupational Hazards
Acute Hepatitis
Diagnosis of Acute Infection
Chronic Hepatitis
HCV and Other Chronic Liver Diseases
Alcoholic Liver Disease
Hepatitis B Coinfection
Cirrhosis and Hepatocellular Carcinoma
Diagnostic Tests
Possible Indications for HCV RNA Testing
Conclusions and Future Direction
e. Hepatitis D
Historical Perspective
Epidemiology
HBV-HDV "Coinfection" vs. "Superinfection"
Methods of Detecting HDV
Prevention
f. Hepatitis E
Background
Prevalence of the Disease
Diagnostic Tests
Epidemiologic Serosurveys
Serologic Cross-Reactivity
g. Hepatitis G
Vaccines and Drugs
34. Herpes Simplex Virus
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
35. Human Herpes Virus-6 (HHV-6)
a. Background
HIV-6 Infections
b. Diagnostic Tests
c. Vaccines and Drugs
36. Influenza Viruses
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
37. Legionella
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
38. Lyme Disease
a. Background
Clinical Description
Clinical Case Definition
Laboratory Criteria for Diagnosis
Case Classification
b. Diagnostic Tests
c. Vaccines and Drugs
39. Lymphogranuloma Venereum (LGV)
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
40. Malaria
a. Background
b. Diagnostic Tests
Potential Diagnositic Problems with Positive
Patients from Non-endemic Areas
- Patient
- Laboratory
- Physician
c. Vaccines and Drugs
41. Measles (Rubeola)
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
42. Meningitis
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
Development of Polysaccharide Vaccines
Quadrivalent Vaccine Development
Meningococcal A.C.Y. & W-135 Vaccines
Efficacy of Group C Vaccine
Efficacy of Group A Vaccine
Combinations of Group A and C Vaccines
Group B Efficacy Trials
Future Direction
43. Microsporidium
a. Background
Prevalence and Geographic Distribution
Sources of Human Infection and Transmission
b. Diagnostic Tests
Light Microscopic Examination of Stool
Specimens By Chromotrope Staining
Stool Concentration Methods
Chemofluorescent Agents
Giemsa Staining of Stool Specimens
Cytologic Diagnosis
Histologic Examination
Electron Microscopy
Examination of Bodily Fluids
Examination of Tissue Sections
Immunofluorescence Detection Procedures
Serology
Cell Culture
Approach to Diagnosis
Evaluation of Patients with Presumptive
Intestinal Microsporidiosis
Evaluation of Patients with Presumptive
Ocular Microsporidiosis
c. Vaccines and Drugs
44. Mononucleosis
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
45. Mumps
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
Efficacy of Vaccination
Future Issues
46. Mycoplasma
a. Background
Ureaplasma Urealyticum & Mycoplasma Hominis
b. Diagnostic Tests
c. Vaccines and Drugs
47. Papillomaviruses
a. Background
HPV in Cancer
Cervical Neoplasm
b. Diagnostic Tests
c. Vaccines and Drugs
Prevention
48. Parvovirus B19
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
49. Pneumonia
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
50. Polyomaviruses
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
51. Pseudomonas Aeruginosa
a. Background
Virulence Factors
b. Diagnostic Tests
c. Vaccines and Drugs
52. Rabies
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
53. Respiratory Syncytial Virus (RSV)
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
54. RhinoViruses
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
55. RotaVirus (REOVIRUS)
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
56. Rubella(MEASLES)
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
Developing Countries
Elimination and Eradication of Measles
New Developments
57. Salmonellosis
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
58. Septicemia
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
59. Shigellosis
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
60. Staphylococcus Aureus
a. Background
The Genus Taphylococcus
b. Diagnostic Tests
c. Vaccines and Drugs
Prevention
61. Streptococci
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
Group A Streptococci
Group B Streptococci
62. Syphilis
a. Background
b. Diagnostic Tests
Biopsy
Rabbit Infectivity Testing
Other Diagnostic Modalities
c. Vaccines and Drugs
Syphilis and HIV Infection
Syphilis As a Cofactor for HIV Transmission
Basic Science Issues
63. Toxoplasmosis
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
64. Trichomonas Vaginalis
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
65. Tuberculosis
a. Background
b. Diagnostic Tests
Microscopic Characteristics
Cultural Characteristics
Detection of Antibodies
Skin Tests
MDRTB
c. Vaccines and Drugs
66. Vibrio
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
67. West Nile Virus
a. Background
- Clinical Syndromes
b. Diagnostic Tests
c. Vaccines and Drugs
68. Yersina
a. Background
b. Diagnostic Tests
c. Vaccines and Drugs
List of Tables
Major Companies Developing or Marketing AIDS Tests
Major Companies Developing or Marketing Adenovirus
Tests
Major Companies Developing or Marketing Bartonella
Tests
Major Companies Developing or Marketing
Campylobacter Tests
Major Companies Developing or Marketing Candida
Tests
Major Companies Developing or Marketing Chlamydia
Tests
Major Companies Developing or Marketing Clostridium
Tests
Major Companies Developing or Marketing Coronavirus
Tests
Major Companies Developing or Marketing Cryptosporidium
Tests
Major Companies Developing or Marketing CMV Tests
Major Companies Developing or Marketing Echovirus
Tests
Major Companies Developing or Marketing Enterovirus
Tests
Major Companies Developing or Marketing EBV Tests
Major Companies Developing or Marketing Giardia
Tests
Major Companies Developing or Marketing Gonorrhea
Tests
Major Companies Developing or Marketing Hantavirus
Tests
Major Companies Developing or Marketing Helicobacter
Pylori Tests
Major Companies Developing or Marketing Hepatitis
Tests
Major Companies Developing or Marketing Herpes
Tests
Major Companies Developing or Marketing Influenza
Tests
Major Companies Developing or Marketing Legionella
Tests
Major Companies Developing or Marketing Lyme Disease
Tests
Major Companies Developing or Marketing Lymphogranuloma
Tests
Major Companies Developing or Marketing Malaria
Tests
Major Companies Developing or Marketing Measles
Tests
Major Companies Developing or Marketing Meningitis
Tests
Major Companies Developing or Marketing Microsporidium
Tests
Major Companies Developing or Marketing
Mononucleosis Tests
Major Companies Developing or Marketing Mumps Tests
Major Companies Developing or Marketing Mycoplasma
Tests
Major Companies Developing or Marketing Papilloma
Virus Tests
Major Companies Developing or Marketing Parvovirus
Tests
Major Companies Developing or Marketing Pneumonia
Tests
Major Companies Developing or Marketing RSV Tests
Major Companies Developing or Marketing Rotavirus
Tests
Major Companies Developing or Marketing Rubella
Tests
Major Companies Developing or Marketing Salmonella
Tests
Major Companies Developing or Marketing Septicemia
Tests
Major Companies Developing or Marketing Shigella
Tests
Major Companies Developing or Marketing Staphylococci
Tests
Major Companies Developing or Marketing
Streptococci Tests
Major Companies Developing or Marketing Syphilis
Tests
Major Companies Developing or Marketing Toxoplasmosis
Tests
Major Companies Developing or Marketing Trichomonas
Tests
Major Companies Developing or Marketing Tuberculosis
Tests
Major Companies Developing or Marketing West Nile
Tests
Major Companies Developing or Marketing Yersinia Tests
To order this report:
Check our Real Time Industry Data
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article